Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor-associated myocarditis  

作　　者：Yan Xu Yanjun Song Xiaoyan Liu Yuequan Shi Yingxian Liu Hao Qian Xiaoxing Gao Minjiang Chen Ruili Pan Jing Zhao Wei Zhong Wei Wu Mengzhao Wang 

机构地区：[1]Department of Respiratory and Critical Care Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Science&Peking Union Medical College,Beijing 100730,P.R.China [2]Department of Cardiology,Peking Union Medical College Hospital,Chinese Academy of Medical Science&Peking Union Medical College,Beijing 100730,P.R.China

出　　处：《Cancer Communications》2022年第9期902-905,共4页癌症通讯（英文）

基　　金：the Youth Program of National Natural Science Foundation of China(to YX)(82003309);the National Key Research and Development Program of China(to WW)(2016YFC0905102);CAMS Innovation Fund for Medical Sciences(to WW)(CIFMS)(2017-I2M-2-002).

摘　　要：Dear Editor,The application of immune checkpoint inhibitors(ICIs),anti-tumor immunotherapy unleashing the host immune system to eradicate tumor cells,has revolutionized the treatment of various advanced cancers and showed remarkable anti-tumor effects[1].However,emphasis must be placed on fatal immune-related adverse events(irAEs),especially some fulminant irAEs like ICI-related cardiovascular AEs[2,3].However,due to the low rate of cardiovascular AEs,little is known about the effective methods for evaluating the risk of catastrophic cardiac events in ICI-associated myocarditis and its management[4,5].

关 键 词：CARDIAC MYOCARDITIS CARDIOVASCULAR 

分 类 号：R730.51[医药卫生—肿瘤]